1.5858
0.31%
-0.0092
Pacific Biosciences Of California Inc stock is traded at $1.5858, with a volume of 10.56M.
It is down -0.31% in the last 24 hours and down -19.70% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.595
Open:
$1.69
24h Volume:
10.56M
Relative Volume:
1.17
Market Cap:
$438.18M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.2487
EPS:
-1.27
Net Cash Flow:
$-260.90M
1W Performance:
-35.37%
1M Performance:
-19.70%
6M Performance:
-21.29%
1Y Performance:
-81.07%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
PACB | 1.585 | 438.18M | 188.87M | -400.38M | -260.90M | -1.27 |
ABT | 117.50 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
SYK | 392.19 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
BSX | 90.70 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
MDT | 87.89 | 112.92B | 32.58B | 3.93B | 5.15B | 2.71 |
EW | 70.12 | 40.88B | 6.60B | 4.16B | 490.10M | 2.34 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-14-23 | Initiated | Guggenheim | Neutral |
Dec-14-23 | Initiated | Stephens | Overweight |
Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
Nov-17-23 | Upgrade | UBS | Neutral → Buy |
Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Sep-28-23 | Initiated | Bernstein | Outperform |
Jul-05-23 | Resumed | JP Morgan | Overweight |
Jun-30-23 | Initiated | Goldman | Buy |
May-10-23 | Initiated | Barclays | Equal Weight |
Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Feb-02-23 | Initiated | UBS | Neutral |
Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
Jan-06-22 | Resumed | Piper Sandler | Neutral |
Oct-15-21 | Resumed | Cowen | Market Perform |
Sep-27-21 | Initiated | Canaccord Genuity | Buy |
Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
Oct-19-18 | Initiated | Cowen | Outperform |
Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
Sep-28-17 | Downgrade | CL King | Buy → Neutral |
Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
Jun-27-16 | Initiated | CL King | Buy |
Apr-15-16 | Initiated | First Analysis Sec | Overweight |
Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
Feb-04-15 | Reiterated | Maxim Group | Buy |
Sep-26-13 | Reiterated | Maxim Group | Buy |
Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
FY2024 EPS Estimates for PACB Lowered by Cantor Fitzgerald - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartzy
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% Following Analyst Upgrade - MarketBeat
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
UBS Downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates - MSN
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock - Investing.com
PacBio’s $459 Million Convertible Note Exchange Offering - Global Legal Chronicle
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00 - MarketBeat
Pacific Biosciences of California Target of Unusually High Options Trading (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Rating Lowered to "Neutral" at UBS Group - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Price Target Raised to $2.50 - MarketBeat
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Wilson Sonsini Advises PacBio on $459 Million Convertible Note Exchange - Wilson Sonsini
PacBio to Present at 4 Major Healthcare Investor Conferences Through Year-End | PACB Stock News - StockTitan
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Pacific Biosciences: Q3 Earnings Snapshot - CTPost
Pacific Biosciences of California (FRA:P09) 5-Day RSI : 64.86 (As of Nov. 08, 2024) - GuruFocus.com
PacBio stock falls 16% post-market after Q3 revenue miss - MSN
Pacific Biosciences of California, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings: E - GuruFocus.com
PacBio Announces Third Quarter 2024 Financial Results - GlobeNewswire
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 - StockTitan
Strong week for Pacific Biosciences of California (NASDAQ:PACB) shareholders doesn't alleviate pain of three-year loss - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company - Simply Wall St
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop - StockTitan
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Re - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep – Company AnnouncementFT.com - Financial Times
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):